Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Looking Ahead: Second-Generation Long-Acting Injectable Antipsychotic Medications for Schizophrenia


This program aims to help pharmacists maintain and enhance professional competencies to ensure optimal medication therapy outcomes and patient safety from the use of long-acting injectable antipsychotics.

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
 
Shenandoah University Bernard J. Dunn School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive credit the following items must be completed

 
1. Register for the event through supharmacy.learningexpressce.com
2. Attend the entire activity
3. Complete all relevant learning assessments
4. Complete an activity evaluation through supharmacy.learningexpressce.com 

Support/Credits

No external funding has been obtained for this activity. The speakers have no conflicts of interest to disclose.

 

 

 

 
 
 

Objectives

  • Summarize the evidence available for the use of second-generation long-acting injectable antipsychotic medications related to schizophrenia
  • Analyze the risks and benefits of second-generation long-acting injectable antipsychotic medications for the management of schizophrenia
  • Evaluate guideline recommendations for using second-generation long-acting injectable antipsychotic medications in schizophrenia

Speaker(s)/Author(s)

Larissa Nguy, PharmD
PGY-1 Resident, Shenandoah University School of Pharmacy

Activity Number

0101-0000-20-001-H01-P

CE Hours

1.00

Location

Novant Health Systems